Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (2412)	12/21/1998 1:28:00 PM
From: jopawa	Read Replies (1) \| Respond to of 4676

This from Bloomberg today: Isis Pharmaceuticals Inc. (ISIP): The U.S. biotechnology company and Zeneca Group Plc, the U.K.'s third-biggest drugmaker, agreed to cooperate in developing and marketing a new type of cancer treatment. The drugmakers said Isis stands to gain more than $40 million from creating and helping to screen antisense- based drug candidates. Antisense-based drugs are synthetic DNA. Isis fell 5/8 to 18 3/8. Zeneca American depositary receipts, each representing one ordinary share, fell 1/8 to 44 1/2. They got the price quote wrong, too bad! John